Stocklytics Platform
Asset logo for symbol CAPR
Capricor Therapeutics
CAPR71
$13.07arrow_drop_up1.62%$0.20
Asset logo for symbol CAPR
CAPR71

$13.07

arrow_drop_up1.62%

Performance History

Chart placeholder
Key Stats
Open$12.64
Prev. Close$12.90
EPS-1.02
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range12.57
13.50
52 Week Range2.68
22.79
Ratios
EPS-1.02

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Capricor Therapeutics (CAPR)

Capricor Therapeutics Inc (CAPR) is a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases. The company is headquartered in Los Angeles, California and was founded in 2005. Capricor's goal is to provide innovative treatment options for patients with unmet medical needs in this field. The company's lead product candidate is CAP-1002, a cell therapy treatment for Duchenne muscular dystrophy (DMD). CAP-1002 is currently in clinical trials and has shown promising results in improving cardiac function in DMD patients.
In addition to its work on DMD, Capricor is also developing other potential therapies for cardiovascular diseases. The company's platform technology, known as cardiosphere-derived cells (CDCs), has shown promise in treating a variety of conditions. CDCs are a type of stem cell that have the potential to regenerate damaged heart tissue and improve cardiac function. Capricor is exploring the use of CDCs in other indications, including heart attack, heart failure, and pulmonary arterial hypertension.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Linda Marbán Ph.D.
Headquarters
San Diego
Employees
74
Exchange
NASDAQ
add Capricor Therapeutics  to watchlist

Keep an eye on Capricor Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Capricor Therapeutics 's (CAPR) price per share?

The current price per share for Capricor Therapeutics (CAPR) is $13.07. The stock has seen a price change of $0.21 recently, indicating a 1.63% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Capricor Therapeutics (CAPR)?

For Capricor Therapeutics (CAPR), the 52-week high is $22.79, which is 74.37% from the current price. The 52-week low is $2.68, the current price is 387.69% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Capricor Therapeutics (CAPR) a growth stock?

Capricor Therapeutics (CAPR) has shown an average price growth of -4.38% over the past three years. It has received a score of 90 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Capricor Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Capricor Therapeutics (CAPR) stock price performance year to date (YTD)?

As of the latest data, Capricor Therapeutics (CAPR) has a year-to-date price change of 155.27%. Over the past month, the stock has experienced a price change of -26.53%. Over the last three months, the change has been 118.93%. Over the past six months, the figure is 178.09%. Looking at a longer horizon, the five-year price change stands at 1.04K%.
help

Is Capricor Therapeutics (CAPR) a profitable company?

Capricor Therapeutics (CAPR) has a net income of -$22.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -575.24% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $25.18M, although specific revenue growth data is currently not available. The gross profit is $24.11M. Operating income is noted at -$24.08M. Furthermore, the EBITDA is -$34.77M.
help

What is the market capitalization of Capricor Therapeutics (CAPR)?

Capricor Therapeutics (CAPR) has a market capitalization of $594.29M. The average daily trading volume is 13.11, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level